Nightfood Holdings Enters Robotics and AI Biopharma Partnership with Oncotelic Therapeutics

Nightfood Holdings Inc. (OTCQB: NGTF), doing business as TechForce Robotics, announced a joint development, manufacturing and licensing agreement with Oncotelic Therapeutics (OTCQB: OTLC) to co-develop AI-enhanced, GMP-compliant robotic systems for pharmaceutical manufacturing and laboratory automation. The collaboration combines TechForce's robotics engineering with Oncotelic's AI-driven pharmaceutical technologies to target improved efficiency, compliance and scalability in biopharma production. This partnership marks TechForce's expansion into regulated healthcare markets while leveraging Oncotelic CEO Dr. Vuong Trieu's experience in oncology, drug development and AI-enabled innovation.

The agreement represents a significant strategic move for both companies, bringing together complementary expertise in robotics and pharmaceutical technology. TechForce Robotics, a wholly owned subsidiary of Nightfood Holdings, is an AI-enhanced service-robotics and automation company focused on developing, deploying, and scaling autonomous robotic solutions for hospitality, foodservice, and commercial applications. Through a vertically integrated platform that combines proprietary robotics technology, real-world operating environments, and scalable manufacturing, TechForce has been accelerating the adoption of automation across multiple industries. The company's expansion into pharmaceutical manufacturing represents a natural progression of its technology platform into new regulated markets with significant automation needs.

Oncotelic Therapeutics brings specialized pharmaceutical expertise to the partnership, particularly in oncology and drug development. The collaboration aims to create systems that can address the complex requirements of pharmaceutical manufacturing, where precision, consistency and regulatory compliance are critical. By integrating AI capabilities with robotic systems, the partners seek to develop solutions that can adapt to changing production requirements while maintaining strict quality standards. This approach could potentially reduce human error, increase production consistency, and enable more flexible manufacturing processes that can respond to varying demand patterns in the pharmaceutical industry.

The partnership's focus on GMP-compliant systems is particularly important for pharmaceutical applications, where manufacturing processes must adhere to strict regulatory standards. Good Manufacturing Practice (GMP) regulations ensure that products are consistently produced and controlled according to quality standards appropriate for their intended use. Developing robotic systems that can operate within these regulatory frameworks represents a significant technical challenge that requires expertise in both robotics engineering and pharmaceutical manufacturing requirements. The collaboration between TechForce and Oncotelic appears designed to address this challenge by combining their respective areas of expertise.

For investors and industry observers, this partnership signals Nightfood Holdings' continued expansion beyond its initial focus on hospitality automation. The company's long-term vision has been to expand into additional verticals requiring similar automation solutions, delivering scalable robotics that improve efficiency, reliability, and revenue generation. The pharmaceutical manufacturing sector represents a substantial market opportunity with growing demand for automation solutions that can address labor shortages, improve quality control, and increase production efficiency. The latest news and updates relating to NGTF are available in the company's newsroom at http://ibn.fm/NGTF.

The broader implications of this partnership extend beyond the immediate business interests of the two companies. As pharmaceutical manufacturing becomes increasingly complex and regulated, the integration of AI and robotics could help address some of the industry's most pressing challenges. These include the need for more flexible manufacturing systems that can handle smaller batch sizes for personalized medicines, improved quality control through continuous monitoring and adjustment, and reduced contamination risks through automated processes. The collaboration between TechForce Robotics and Oncotelic Therapeutics represents one approach to addressing these challenges through technology integration and cross-industry partnership.